NCT03692949View on ClinicalTrials.gov

A Study of LY3451838 in Healthy Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

53

Participants

Timeline

Start Date

December 11, 2018

Primary Completion Date

February 26, 2020

Study Completion Date

February 26, 2020

Conditions
Healthy
Interventions
DRUG

LY3451838

Administered IV Part A

DRUG

LY3451838

Administered IV Part A

DRUG

LY3451838

Administered IV Part A

DRUG

LY3451838

Administered IV Part A

DRUG

LY3451838

Administered IV Part A

DRUG

LY3451838

Administered IV Part A

DRUG

LY3451838

Administered SC Part B

DRUG

Placebo

Administered IV in Part A and SC in Part B

Trial Locations (1)

138623

Lilly Centre for Clinical Pharmacology, Singapore

All Listed Sponsors
lead

Eli Lilly and Company

INDUSTRY

NCT03692949 - A Study of LY3451838 in Healthy Participants | Biotech Hunter | Biotech Hunter